Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,997
  • Shares Outstanding, K 32,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,190 K
  • 60-Month Beta 3.31
  • Price/Sales 25.00
  • Price/Cash Flow N/A
  • Price/Book 5.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +54.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.35 +548.57%
on 11/14/19
8.18 -72.25%
on 12/02/19
+0.19 (+9.13%)
since 11/08/19
3-Month
0.35 +548.57%
on 11/14/19
8.18 -72.25%
on 12/02/19
+0.54 (+31.21%)
since 09/10/19
52-Week
0.35 +548.57%
on 11/14/19
8.18 -72.25%
on 12/02/19
-2.16 (-48.76%)
since 12/10/18

Most Recent Stories

More News
Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor ASLAN Pharmaceuticals.

ASLN : 2.27 (-2.99%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

BAYRY : 19.1300 (+0.55%)
AVEO : 0.72 (+1.02%)
RARE : 42.50 (+2.34%)
ASLN : 2.27 (-2.99%)
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ACOR : 1.69 (-1.74%)
ICPT : 114.88 (+3.62%)
AVEO : 0.72 (+1.02%)
ASLN : 2.27 (-2.99%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ASLN : 2.27 (-2.99%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASLN : 2.27 (-2.99%)
Top Ranked Momentum Stocks to Buy for March 29th

Top Ranked Momentum Stocks to Buy for March 29th

SAFM : 164.25 (-0.79%)
ASLN : 2.27 (-2.99%)
ACIA : 67.34 (+0.64%)
Top Ranked Momentum Stocks to Buy for March 28th

Top Ranked Momentum Stocks to Buy for March 28th

ASLN : 2.27 (-2.99%)
ANF : 17.79 (+2.42%)
ADXS : 0.64 (-21.51%)
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

RHHBY : 38.4000 (+0.01%)
ACOR : 1.69 (-1.74%)
VNDA : 17.42 (+0.14%)
ASLN : 2.27 (-2.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ASLN with:

Business Summary

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003...

See More

Key Turning Points

2nd Resistance Point 2.56
1st Resistance Point 2.41
Last Price 2.27
1st Support Level 2.16
2nd Support Level 2.06

See More

52-Week High 8.18
Fibonacci 61.8% 5.19
Fibonacci 50% 4.27
Fibonacci 38.2% 3.34
Last Price 2.27
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar